Bifidobacterium longum CCM 7952 promotes epithelial barrier function and prevents acute dss-induced colitis in strictly strain-Specific manner

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Srutkova, Dagmar ^a   Schwarzer, Martin ^a   Hudcovic, Tomas ^a   Zakostelska, Zuzana ^a   Drab, Vladimir ^b   Spanova, Alena ^c   Rittich, Bohuslav ^c   Kozakova, Hana ^a   Schabussova, Irma ^d  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b Dairy Research Institute   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; PROBIOTIC AGENT; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 2; DEXTRAN SULFATE; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; BONE MARROW DERIVED DENDRITIC CELL; CELL STIMULATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; EXPERIMENTAL COLITIS; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; STRAIN DIFFERENCE; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; CHEMICALLY INDUCED; CLASSIFICATION; DENDRITIC CELL; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; INTESTINE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIFIDOBACTERIUM; COLITIS; DENDRITIC CELLS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINES; MICE; MICE, INBRED BALB C; NOD2 SIGNALING ADAPTOR PROTEIN; PROBIOTICS; TOLL-LIKE RECEPTOR 2;

EID: 84942031745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134050     Document Type: Article

References (80)

1. Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet. 2012; 380(9853):1590-605. doi:10.1016/s0140-6736(12)60026-9.
2. Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012; 18(1):1-15. Epub 2011/05/14. doi:10.1111/j.1601-0825.2011.01811.x PMID: 21564424.
3. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1):46-54 e42; quiz e30. Epub 2011/10/18. doi:10.1053/j.gastro.2011.10.001PMID: 22001864.
4. Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013; 43(3-4):245-51. Epub 2012/11/28. doi:10.1016/j.ijpara.2012.10.016 PMID: 23178819; PubMed Central PMCID: PMC3683647.
5. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012; 9(10):599-608. Epub 2012/08/22. doi:10.1038/nrgastro.2012.152 PMID: 22907164.
6. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci. 1997; 42(4):817-22. PMID: 9125655.
7. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008; 134(2):577- 94. Epub 2008/02/05. doi:10.1053/j.gastro.2007.11.059 PMID: 18242222.
8. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003; 361(9356):512-9. doi:10.1016/S0140-6736(03)12489-0PMID: 12583961.
9. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011; 5:185-210. Epub 2011/05/10. doi:10.2147/DDDT.S11290PMID: 21552489; PubMed Central PMCID: PMC3084301.
10. Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol. 2014; 20(12):3146-52. Epub 2014/04/04. doi:10.3748/wjg.v20.i12.3146 PMID: 24696600; PubMed Central PMCID: PMC3964386.
11. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005; 100 (7):1539-46. Epub 2005/06/30. doi:10.1111/j.1572-0241.2005.41794.x PMID: 15984978.
12. Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc. 2014; 73(4):490-7. Epub 2014/06/28. doi:10.1017/S0029665114000639 PMID: 24969143.
13. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999; 13(8):1103-8. PMID: 10468688.
14. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009; 104(2):437-43. Epub 2009/01/29. doi:10.1038/ajg.2008.118 PMID: 19174792.
15. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut. 2002; 51(3):405-9. PMID: 12171964; PubMed Central PMCID: PMC1773351.
16. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci. 2008; 53(9):2524-31. doi:10.1007/s10620-007-0171-0 PMID: 18270836.
17. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2006;(4: ):CD004826. doi:10.1002/14651858.CD004826.pub2 PMID: 17054217.
18. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011; 5(2):115-21. Epub 2011/04/02. doi:10.1016/j.crohns.2010.11.004 PMID: 21453880.
19. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: Traps and tricks. J Biomed Biotechnol. 2012; 2012:718617. Epub 2012/06/06. doi:10.1155/2012/718617 PMID: 22665990; PubMed Central PMCID: PMC3361365.
20. Neurath MF. Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer. Dig Dis. 2012; 30 Suppl 1:91-4. Epub 2012/10/25. doi:10.1159/000341131 PMID: 23075875.
21. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009; 15 (3):341-52. Epub 2008/10/24. doi:10.1002/ibd.20753 PMID: 18942757; PubMed Central PMCID: PMC2643312.
22. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990; 98 (3):694-702. PMID: 1688816.
23. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annual review of immunology. 2002; 20:495-549. doi:10.1146/annurev.immunol.20.100301.064816 PMID: 11861611.
24. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2(3):541-6. doi:10.1038/nprot.2007.41 PMID: 17406617.
25. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. The Journal of surgical research. 2007; 140(1):12-9. Epub 2007/04/10. doi:10.1016/j.jss.2006.07.050 PMID: 17418867.
26. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993; 341(8858):1437-9. PMID: 8099141.
27. Turroni F, Foroni E, Pizzetti P, Giubellini V, Ribbera A, Merusi P, et al. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol. 2009; 75(6):1534-45. doi:10.1128/AEM.02216-08PMID: 19168652; PubMed Central PMCID: PMC2655441.
28. Turroni F, Marchesi JR, Foroni E, Gueimonde M, Shanahan F, Margolles A, et al. Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J. 2009; 3(6):745-51. doi:10.1038/ismej.2009.19 PMID: 19295640.
29. Ventura M, Turroni F, Lugli GA, van Sinderen D. Bifidobacteria and humans: our special friends, from ecological to genomics perspectives. J Sci Food Agric. 2014; 94(2):163-8. doi:10.1002/jsfa.6356 PMID: 23963950.
30. Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol. 1999; 65(10):4506-12. PMID: 10508082; PubMed Central PMCID: PMC91600.
31. Makino H, Kushiro A, Ishikawa E, Muylaert D, Kubota H, Sakai T, et al. Transmission of intestinal Bifidobacterium longum subsp. longum strains from mother to infant, determined by multilocus sequencing typing and amplified fragment length polymorphism. Applied and environmental microbiology. 2011; 77 (19):6788-93. doi:10.1128/AEM.05346-11 PMID: 21821739; PubMed Central PMCID: PMC3187114.
32. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil D A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut. 2005; 54(2):242-9. doi:10.1136/gut.2004.044834 PMID: 15647189; PubMed Central PMCID: PMC1774839.
33. Fujiwara M, Kaneko T, Iwana H, Taketomo N, Tsunoo H, Kanno J, et al. Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion. 2003; 67(1-2):90-5. 69704. PMID: 12743446.
34. Schwarzer M, Srutkova D, Schabussova I, Hudcovic T, Akgun J, Wiedermann U, et al. Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1. Vaccine. 2013; 31(46):5405-12. doi:10.1016/j.vaccine.2013.09.014 PMID: 24055352.
35. Schabussova I, Hufnagl K, Wild C, Nutten S, Zuercher AW, Mercenier A, et al. Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. Vaccine. 2011; 29(10):1981-90. doi:10.1016/j.vaccine.2010.12.101 PMID: 21216308.
36. Srutkova D, Spanova A, Spano M, Drab V, Schwarzer M, Kozakova H, et al. Efficiency of PCR-based methods in discriminating Bifidobacterium longum ssp. longum and Bifidobacterium longum ssp. infantis strains of human origin. J Microbiol Methods. 2011; 87(1):10-6. doi:10.1016/j.mimet.2011.06.014 PMID: 21756944.
37. Krizova J, Spanova A, Rittich B. Evaluation of amplified ribosomal DNA restriction analysis (ARDRA) and species-specific PCR for identification of Bifidobacterium species. Syst Appl Microbiol. 2006; 29 (1):36-44. doi:10.1016/j.syapm.2005.07.003 PMID: 16423654.
38. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine. 2003; 22(1):87-95. PMID: 14604575.
39. Schabussova I, Hufnagl K, Tang ML, Hoflehner E, Wagner A, Loupal G, et al. Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy. PloS one. 2012; 7(7):e40271. doi:10.1371/journal.pone.0040271 PMID: 22792257; PubMed Central PMCID: PMC3391241.
40. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69(2):238-49. PMID: 8350599.
41. Hudcovic T, Stepankova R, Cebra J, Tlaskalova-Hogenova H. The role of microflora in the development of intestinal inflammation: Acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia microbiologica. 2001; 46 (6):565-72. PMID: 11898350.
42. Cinova J, De Palma G, Stepankova R, Kofronova O, Kverka M, Sanz Y, et al. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PloS one. 2011; 6(1):e16169. doi:10.1371/journal.pone.0016169PMID: 21249146; PubMed Central PMCID: PMC3020961.
43. Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PloS one. 2011; 6(11):e27961. doi:10.1371/journal.pone.0027961 PMID: 22132181; PubMed Central PMCID: PMC3222668.
44. Kole A, Maloy KJ. Control of intestinal inflammation by interleukin-10. Current topics in microbiology and immunology. 2014; 380:19-38. Epub 2014/07/10. doi:10.1007/978-3-662-43492-5-2 PMID: 25004812.
45. Persson EK, Scott CL, Mowat AM, Agace WW. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur J Immunol. 2013; 43(12):3098-107. doi:10.1002/eji.201343740 PMID: 23966272; PubMed Central PMCID: PMC3933733.
46. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009; 124(1):3-20; quiz 1-2. doi:10.1016/j.jaci.2009.05.038 PMID: 19560575; PubMed Central PMCID: PMC4266989.
47. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014; 146(6):1489-99. doi:10.1053/j.gastro.2014.02.009 PMID: 24560869; PubMed Central PMCID: PMC4034132.
48. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Kohler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010; 157(2):240-4 e1. Epub 2010/04/20. doi:10.1016/j.jpeds.2010.02.046 PMID: 20400104.
49. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatmentnaive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15(3):382-92. Epub 2014/03/19. doi:10.1016/j.chom.2014.02.005 PMID: 24629344; PubMed Central PMCID: PMC4059512.
50. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol. 2007; 115(1):1-11. Epub 2006/12/02. doi:10.1016/j.ijfoodmicro.2006.10.006 PMID: 17137666.
51. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8):506-14. doi:10.1038/nrgastro.2014.66PMID: 24912386.
52. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004; 53(11):1602-9. Epub 2004/10/14. doi:10.1136/gut.2003.037325 PMID: 15479680; PubMed Central PMCID: PMC1774301.
53. Latvala S. Potentially probiotic bacteria induce efficient maturation but differential cytokine production in human monocyte-derived dendritic cells. World Journal of Gastroenterology. 2008; 14(36):5570. doi:10.3748/wjg.14.5570 PMID: 18810777.
54. Lopez P, Gueimonde M, Margolles A, Suarez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010; 138(1-2):157-65. Epub 2010/01/15. doi:10.1016/j.ijfoodmicro.2009.12.023 PMID: 20071048.
55. Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clinical and experimental immunology. 2007; 150(3):531-8. Epub 2007/10/25. doi:10.1111/j.1365-2249.2007.03522.x PMID: 17956582; PubMed Central PMCID: PMC2219384.
56. Preising J, Philippe D, Gleinser M, Wei H, Blum S, Eikmanns BJ, et al. Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol. 2010; 76(9):3048-51. doi:10.1128/AEM.03127-09 PMID: 20228095; PubMed Central PMCID: PMC2863435.
57. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993; 75(2):263-74. PMID: 8402911.
58. Steidler L. Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10. Science. 2000; 289(5483):1352-5. doi:10.1126/science.289.5483.1352 PMID: 10958782.
59. Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012; 108(3):459-70. Epub 2011/11/08. doi:10.1017/S0007114511005824 PMID: 22054064.
60. Kekkonen R-A. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World Journal of Gastroenterology. 2008; 14(13):2029. doi:10.3748/wjg.14.2029 PMID: 18395902.
61. Mann ER, Landy JD, Bernardo D, Peake ST, Hart AL, Al-Hassi HO, et al. Intestinal dendritic cells: Their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett. 2013; 150(1-2):30-40. Epub 2013/01/29. doi:10.1016/j.imlet.2013.01.007 PMID: 23352670.
62. Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014; 20(1):166-75. Epub 2013/08/27. doi:10.1097/MIB.0b013e3182a69dcaPMID: 23974993; PubMed Central PMCID: PMC4098861.
63. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007; 13 (2):236-43. PMID: 17226902; PubMed Central PMCID: PMC4065951.
64. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010; 107(5):2159-64. doi:10.1073/pnas.0904055107 PMID: 20080669; PubMed Central PMCID: PMC2836639.
65. Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PloS one. 2009; 4(9):e7056. Epub 2009/09/17. doi:10.1371/journal.pone.0007056 PMID: 19756155; PubMed Central PMCID: PMC2738944.
66. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American journal of physiology Gastrointestinal and liver physiology. 2010; 298(6):G851-9. doi:10.1152/ajpgi.00327.2009 PMID: 20224007.
67. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411(6837):603-6. doi:10.1038/35079114PMID: 11385577.
68. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine- rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411(6837):599-603. doi:10.1038/35079107 PMID: 11385576.
69. Biswas A, Kobayashi KS. Regulation of intestinal microbiota by the NLR protein family. International immunology. 2013; 25(4):207-14. doi:10.1093/intimm/dxs116PMID: 23325116; PubMed Central PMCID: PMC3597849.
70. Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. The Journal of clinical investigation. 2013; 123(2):700-11. doi:10.1172/JCI62236 PMID: 23281400; PubMed Central PMCID: PMC3561825.
71. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. The Journal of biological chemistry. 2003; 278(8):5509-12. doi:10.1074/jbc.C200673200 PMID: 12514169.
72. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. 2011; 60(8):1050-9. doi:10.1136/gut.2010.232918 PMID: 21471573.
73. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013; 4:280. Epub 2013/09/26. doi:10.3389/fimmu.2013.00280 PMID: 24062746; PubMed Central PMCID: PMC3775315.
74. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009; 1165:294-300. Epub 2009/06/23. doi:10.1111/j.1749-6632.2009.04062.x PMID: 19538319.
75. Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis. 2012; 18(10):1932-9. Epub 2012/02/22. doi:10.1002/ibd.22909 PMID: 22344959.
76. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014; 7(1):6-19. doi:10.1038/mi.2013.73 PMID: 24084775.
77. Gyires K, Toth EV, Zadori SZ. Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Curr Pharm Des. 2014; 20(7):1063-81. PMID: 23782146.
78. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PloS one. 2007; 2(12):e1308. doi:10.1371/journal.pone.0001308 PMID: 18074031; PubMed Central PMCID: PMC2110898.
79. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007; 9(3):804-16. Epub 2006/11/08. doi:10.1111/j.1462-5822.2006.00836.x PMID: 17087734.
80. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American journal of physiology Gastrointestinal and liver physiology. 2009; 296 (5):G1140-9. doi:10.1152/ajpgi.90534.2008 PMID: 19221015.